Napoli C, Cicala C, D'Armiento F P, Roviezzo F, Somma P, de Nigris F, Zuliani P, Bucci M, Aleotti L, Casini A, Franconi F, Cirino G
Department of Clinical and Experimental Medicine, Federico II University of Naples, Italy.
Gen Pharmacol. 1999 Dec;33(6):467-77. doi: 10.1016/s0306-3623(99)00043-9.
The effects of angiotensin-converting enzyme (ACE)-inhibition with zofenopril on the development of atherosclerosis and low-density lipoprotein (LDL) oxidation were determined in Watanabe Heritable Hyperlipidemic (WHHL) rabbits. Rabbits received either placebo (n = 6) or 0.5 mg/kg/day of zofenopril (n = 6). After 6 weeks of treatment, the computer-assisted analysis revealed that zofenopril reduced the aortic and common carotid corrected cumulative lesion area by 34% and 39%, respectively (p < 0.05 vs placebo-treated group). The intimal/medial ratio of the largest fatty streaks was 0.426+/-0.158 in the zofenopril-treated group and 0.875+/-0.238 in the placebo-treated group (p < 0.05). Furthermore, we found in the zofenopril-treated group smaller lesions with an intimal/medial ratio of zofenopril also reduced plasmatic LDL oxidation, as shown by significant reduction of malondialdehyde content (p < 0.01) and relative agarose gel mobility (p < 0.05), as well as by the prolongation of the lag-time (p < 0.05). Compared to zofenopril-treated rabbits, arterial sections of the placebo-group had significant increase in the intimal presence of macrophages-derived foam cells (p < 0.05), ox-LDL (p < 0.01), and native LDL (p < 0.01) detected by immunocytochemistry with RAM-11, MDA2 and NP1533975 monoclonal antibodies, respectively. To investigate the amount of platelet accumulation in the atherosclerotic plaque we also measured platelet-associated radioactivity. Autologous platelets were labeled with 111Indiumoxine and injected intravenously. After 2 hours, WHHL were sacrificed and arterial sections were counted for platelet-associated radioactivity. In the placebo-treated group, platelet radioactivity was 0.52+/-0.12 equivalent of radioactivity per mg of tissue in the common carotid and 0.25+/-0.18 in the abdominal aorta; in contrast, rabbits treated by zofenopril had 0.20+/-0.12 in the common carotid and 0.06+/-0.01 in the abdominal aorta. These data indicate that ACE-inhibition with zofenopril has antiatherosclerotic and antioxidant effects in WHHL-rabbits. Our results also shows that these effects could be linked to a reduced wall-associated platelet deposition at the site of atherosclerotic lesions.
在遗传性高脂血症(WHHL)兔中,研究了佐芬普利抑制血管紧张素转换酶(ACE)对动脉粥样硬化发展及低密度脂蛋白(LDL)氧化的影响。兔子分为两组,一组接受安慰剂(n = 6),另一组接受0.5 mg/kg/天的佐芬普利(n = 6)。治疗6周后,计算机辅助分析显示,佐芬普利使主动脉和颈总动脉校正后的累积病变面积分别减少了34%和39%(与安慰剂治疗组相比,p < 0.05)。佐芬普利治疗组最大脂肪条纹的内膜/中膜比为0.426±0.158,安慰剂治疗组为0.875±0.238(p < 0.05)。此外,我们发现佐芬普利治疗组病变较小,其内膜/中膜比也降低了血浆LDL氧化,丙二醛含量显著降低(p < 0.01)、相对琼脂糖凝胶迁移率降低(p < 0.05)以及延迟时间延长(p < 0.05)均表明了这一点。与佐芬普利治疗的兔子相比,安慰剂组动脉切片中巨噬细胞衍生的泡沫细胞(p < 0.05)、氧化型LDL(p < 0.01)和天然LDL(p < 0.01)的内膜存在通过分别用RAM-11、MDA2和NP1533975单克隆抗体进行免疫细胞化学检测显示显著增加。为了研究动脉粥样硬化斑块中血小板聚集的量,我们还测量了血小板相关放射性。用111铟氧嗪标记自体血小板并静脉注射。2小时后,处死WHHL兔并对动脉切片进行血小板相关放射性计数。在安慰剂治疗组中,颈总动脉每毫克组织的血小板放射性为0.52±0.12放射性当量,腹主动脉为0.25±0.18;相比之下,佐芬普利治疗的兔子颈总动脉为0.20±0.12,腹主动脉为0.06±0.01。这些数据表明,佐芬普利抑制ACE对WHHL兔具有抗动脉粥样硬化和抗氧化作用。我们的结果还表明,这些作用可能与动脉粥样硬化病变部位壁相关血小板沉积减少有关。